Bactericidal efficacy of ABI-0043, a novel rifamycin, in a murine pneumococcal pneumonia model.

Abstract	Novel rifamycins such as ABI-0043, ABI-0369, and ABI-0699 had comparable in vivo bactericidal activity with ceftriaxone against a penicillin-G-resistant, mefA-positive Streptococcus pneumoniae in a murine pneumonia model. ABI-0043 demonstrated a dose-dependent response with a high correlation to bacterial kill (+0.1 to -3.7 log 10CFU).
Authors	Su Young Lee, Pamela R Tessier, Christopher K Murphy, David P Nicolau
Journal	The Journal of antibiotics (J Antibiot (Tokyo)) Vol. 59 Issue 12 Pg. 804-7 (Dec 2006) ISSN: 0021-8820 [Print] England
PMID	17323649 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	ABI 0043 Anti-Bacterial Agents Rifamycins Ceftriaxone
Topics	Animals Anti-Bacterial Agents (pharmacology) Ceftriaxone (therapeutic use) Disease Models, Animal Dose-Response Relationship, Drug Female Mice Mice, Inbred ICR Penicillin Resistance Pneumonia, Pneumococcal (drug therapy) Rifamycins (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!